Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Clinical Outcomes
100%
Metastatic Melanoma
100%
Response-outcome
100%
Stereotactic Body Radiation Therapy
100%
18F-FDG Positron Emission Tomography
100%
Metastasis Control
62%
Equivalent Dose
50%
Single Fraction
50%
Overall Survival
37%
Metastasis
25%
Malignant Melanoma
25%
Complete Response
25%
Metabolic Response
25%
Positron Emission Tomography/computed Tomography (PET/CT)
25%
Positron Emission Tomography Scan
25%
Chemotherapy
12%
Ipilimumab
12%
Oligometastases
12%
Progression-free Survival
12%
Ablation
12%
Clinical Data
12%
Prognostic Factors
12%
Granulocyte Colony-stimulating Factor (G-CSF)
12%
Functional Imaging
12%
Cumulative Incidence
12%
Extracranial
12%
Cox Proportional Hazards Model
12%
Likelihood Ratio
12%
Kaplan-Meier Method
12%
Survival Estimation
12%
Wilcoxon Test
12%
Biologically Effective Dose
12%
Therapy Assessment
12%
PET Response Criteria in Solid Tumors
12%
Scan Range
12%
Positron Emission Tomography/computed Tomography Scan
12%
Outcome Response
12%
18F-fludeoxyglucose Positron Emission Tomography
12%
Medicine and Dentistry
Metastatic Melanoma
100%
Positron Emission Tomography
100%
Fluorodeoxyglucose F 18
100%
Stereotactic Body Radiation Therapy
100%
Melanoma
55%
Equivalent Dose
44%
Overall Survival
33%
Positron Emission Tomography-Computed Tomography
22%
Solid Malignant Neoplasm
11%
Immunotherapy
11%
Computer Assisted Tomography
11%
Progression Free Survival
11%
Ipilimumab
11%
Metastatic Carcinoma
11%
Prognostic Factor
11%
Functional Imaging
11%
Granulocyte Macrophage Colony Stimulating Factor
11%
Cumulative Incidence
11%
Proportional Hazards Model
11%
Kaplan Meier Method
11%
Rank Sum Test
11%
Survival Estimate
11%
Fludeoxyglucose (18F)
11%
Polyethylene Terephthalate
11%
Chemotherapy
11%